HKEX: 1530
2026 Interim Report
Earlier from 3sbio
- Next Day Disclosure Return
- 3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone
- Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
- Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance